HK1250724A1 - 用於製備經修飾的血管性血友病因子的方法 - Google Patents
用於製備經修飾的血管性血友病因子的方法Info
- Publication number
- HK1250724A1 HK1250724A1 HK18109997.4A HK18109997A HK1250724A1 HK 1250724 A1 HK1250724 A1 HK 1250724A1 HK 18109997 A HK18109997 A HK 18109997A HK 1250724 A1 HK1250724 A1 HK 1250724A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- von willebrand
- willebrand factor
- preparing modified
- modified von
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15168934 | 2015-05-22 | ||
PCT/EP2016/061440 WO2016188905A1 (en) | 2015-05-22 | 2016-05-20 | Methods for preparing modified von willebrand factor |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1250724A1 true HK1250724A1 (zh) | 2019-01-11 |
Family
ID=53191564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18109997.4A HK1250724A1 (zh) | 2015-05-22 | 2018-08-02 | 用於製備經修飾的血管性血友病因子的方法 |
Country Status (17)
Country | Link |
---|---|
US (3) | US10772936B2 (zh) |
EP (2) | EP3298036B1 (zh) |
JP (1) | JP6651548B2 (zh) |
KR (1) | KR20180012303A (zh) |
CN (1) | CN107810194B (zh) |
AU (1) | AU2016267539B2 (zh) |
BR (1) | BR112017024714A2 (zh) |
CA (1) | CA2986625A1 (zh) |
DK (1) | DK3298036T3 (zh) |
ES (1) | ES2912300T3 (zh) |
HK (1) | HK1250724A1 (zh) |
IL (1) | IL255711A (zh) |
MX (1) | MX2017014872A (zh) |
RU (1) | RU2017145002A (zh) |
SG (2) | SG10201910900WA (zh) |
TW (1) | TW201713686A (zh) |
WO (1) | WO2016188905A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201828974A (zh) | 2016-11-11 | 2018-08-16 | 瑞士商Csl貝林重組技能公司 | 用於血管外施予以治療或預防凝血疾病之截短型類血友病因子(von Willebrand factor)多肽類 |
DK3538133T3 (da) | 2016-11-11 | 2021-04-19 | CSL Behring Lengnau AG | Trunkeret von willebrand faktor polypeptider til behandling af hæmofili |
US11141466B2 (en) | 2017-06-22 | 2021-10-12 | CSL Behring Lengnau AG | Modulation of FVIII immunogenicity by truncated VWF |
WO2021001522A1 (en) | 2019-07-04 | 2021-01-07 | CSL Behring Lengnau AG | A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii |
EP4038182A1 (en) * | 2019-09-30 | 2022-08-10 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
WO1994015625A1 (en) | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Factor viii - polymeric conjugates |
JPH11501506A (ja) | 1994-12-12 | 1999-02-09 | ベス イスラエル デアコネス メディカル センター | キメラ型サイトカインおよびその利用 |
AU6455896A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered metal-binding properties |
SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
US20040092442A1 (en) | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
EP0910628B1 (en) | 1996-04-24 | 2006-03-08 | The Regents of The University of Michigan | Inactivation resistant factor viii |
AU736993B2 (en) | 1997-01-16 | 2001-08-09 | Novo Nordisk A/S | Practical in vitro sialylation of recombinant glycoproteins |
ATE283034T1 (de) | 1998-04-27 | 2004-12-15 | Opperbas Holding Bv | Pharmazeutische zusammensetzungen enthaltend faktor viii und neutrale liposomen |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
AU2002248329B2 (en) | 2001-01-12 | 2007-06-28 | The American National Red Cross | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII |
WO2002103024A2 (en) | 2001-06-14 | 2002-12-27 | The Scripps Research Institute | Stabilized proteins with engineered disulfide bonds |
EP1572936A2 (en) | 2002-03-05 | 2005-09-14 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
WO2003093313A2 (en) | 2002-04-29 | 2003-11-13 | Baxter International Inc. | Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein |
CN101857851A (zh) * | 2002-12-23 | 2010-10-13 | 布里斯托尔-迈尔斯斯奎布公司 | 用于蛋白质生产的哺乳动物细胞培养方法 |
US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
CN102139114A (zh) | 2003-02-26 | 2011-08-03 | 尼克塔治疗公司 | 聚合物-因子viii部分缀合物 |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
EP3552627A1 (en) | 2003-05-06 | 2019-10-16 | Bioverativ Therapeutics Inc. | Clotting factor-fc chimeric proteins to treat hemophilia |
AU2004251145C1 (en) | 2003-06-12 | 2011-04-14 | Eli Lilly And Company | GLP-1 analog fusion proteins |
BRPI0417916A (pt) | 2003-12-31 | 2007-04-10 | Merck Patent Gmbh | proteìna de fusão de fc-eritropoietina com farmacocinética melhorada |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
PL1824988T3 (pl) | 2004-11-12 | 2018-01-31 | Bayer Healthcare Llc | Ukierunkowana na miejsce modyfikacja czynnika VIII |
EP1835938B1 (en) | 2004-12-27 | 2013-08-07 | Baxter International Inc. | Polymer-von willebrand factor-conjugates |
AU2006233638A1 (en) | 2005-04-14 | 2006-10-19 | Csl Behring Gmbh | Modified coagulation Factor VIII with enhanced stability and its derivates |
EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
CA2647314A1 (en) | 2006-03-31 | 2007-11-08 | Baxter International Inc. | Pegylated factor viii |
WO2007144173A1 (en) | 2006-06-14 | 2007-12-21 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
CA2657248C (en) | 2006-07-13 | 2018-10-30 | Wyeth | Production of glycoproteins |
JP5448839B2 (ja) | 2006-12-22 | 2014-03-19 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | インビボで長い半減期を有する修飾された凝固因子 |
PT2574677T (pt) | 2007-12-27 | 2017-10-19 | Baxalta Inc | Processos para cultura de células |
CN103739712B (zh) | 2008-06-24 | 2016-10-05 | 德国杰特贝林生物制品有限公司 | 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物 |
MX2012005527A (es) | 2009-11-13 | 2012-08-08 | Grifols Therapeutics Inc | Preparaciones que contienen el factor de von willebrand (fvw) procedimientos, kits y aplicaciones relacionados con las mismas. |
EP2563906B1 (en) | 2010-04-26 | 2017-11-08 | Novartis AG | Process for cultivation of cho cells |
WO2013093760A2 (en) | 2011-12-19 | 2013-06-27 | Grifols, S.A. | Compositions, methods, and kits for preparing sialylated recombinant proteins |
CA2863328A1 (en) | 2012-01-12 | 2013-07-18 | Biogen Idec Ma Inc. | Chimeric factor viii polypeptides and uses thereof |
EP2814502B1 (en) | 2012-02-15 | 2017-09-13 | CSL Behring GmbH | Von willebrand factor variants having improved factor viii binding affinity |
WO2013083858A1 (en) | 2012-04-24 | 2013-06-13 | Novo Nordisk A/S | Compounds suitable for treatment of haemophilia |
SE537059C2 (sv) * | 2012-12-21 | 2014-12-23 | Nätstations Alliansen Ab | Elcentral |
US20160207977A1 (en) | 2013-06-12 | 2016-07-21 | Novo Nordisk A/S | Compounds Suitable for Treatment of Haemophilia |
-
2016
- 2016-05-20 WO PCT/EP2016/061440 patent/WO2016188905A1/en active Application Filing
- 2016-05-20 RU RU2017145002A patent/RU2017145002A/ru not_active Application Discontinuation
- 2016-05-20 MX MX2017014872A patent/MX2017014872A/es unknown
- 2016-05-20 AU AU2016267539A patent/AU2016267539B2/en active Active
- 2016-05-20 ES ES16725477T patent/ES2912300T3/es active Active
- 2016-05-20 SG SG10201910900WA patent/SG10201910900WA/en unknown
- 2016-05-20 SG SG11201708754XA patent/SG11201708754XA/en unknown
- 2016-05-20 BR BR112017024714A patent/BR112017024714A2/pt not_active Application Discontinuation
- 2016-05-20 KR KR1020177037165A patent/KR20180012303A/ko unknown
- 2016-05-20 CA CA2986625A patent/CA2986625A1/en active Pending
- 2016-05-20 US US15/576,061 patent/US10772936B2/en active Active
- 2016-05-20 EP EP16725477.0A patent/EP3298036B1/en active Active
- 2016-05-20 CN CN201680029616.9A patent/CN107810194B/zh active Active
- 2016-05-20 DK DK16725477.0T patent/DK3298036T3/da active
- 2016-05-20 EP EP22160272.5A patent/EP4089109A3/en active Pending
- 2016-05-20 JP JP2017560681A patent/JP6651548B2/ja active Active
- 2016-05-23 TW TW105116002A patent/TW201713686A/zh unknown
-
2017
- 2017-11-16 IL IL255711A patent/IL255711A/en unknown
-
2018
- 2018-08-02 HK HK18109997.4A patent/HK1250724A1/zh unknown
-
2020
- 2020-07-10 US US16/925,411 patent/US10905747B2/en active Active
- 2020-12-29 US US17/136,334 patent/US11564976B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
DK3298036T3 (da) | 2022-06-07 |
IL255711A (en) | 2018-04-30 |
US11564976B2 (en) | 2023-01-31 |
CN107810194A (zh) | 2018-03-16 |
MX2017014872A (es) | 2018-07-06 |
SG10201910900WA (en) | 2020-01-30 |
US10772936B2 (en) | 2020-09-15 |
BR112017024714A2 (pt) | 2018-09-11 |
JP6651548B2 (ja) | 2020-02-19 |
EP3298036A1 (en) | 2018-03-28 |
CN107810194B (zh) | 2021-10-08 |
JP2018515125A (ja) | 2018-06-14 |
ES2912300T3 (es) | 2022-05-25 |
AU2016267539A1 (en) | 2017-11-16 |
SG11201708754XA (en) | 2017-12-28 |
TW201713686A (en) | 2017-04-16 |
EP3298036B1 (en) | 2022-04-06 |
US10905747B2 (en) | 2021-02-02 |
AU2016267539B2 (en) | 2019-12-05 |
RU2017145002A (ru) | 2019-06-24 |
US20200368327A1 (en) | 2020-11-26 |
CA2986625A1 (en) | 2016-12-01 |
US20210121535A1 (en) | 2021-04-29 |
EP4089109A3 (en) | 2023-03-01 |
US20180153968A1 (en) | 2018-06-07 |
KR20180012303A (ko) | 2018-02-05 |
EP4089109A2 (en) | 2022-11-16 |
WO2016188905A1 (en) | 2016-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1253507A1 (zh) | 抗 ror1 抗體 | |
HK1254836A1 (zh) | 抗-ror1抗體 | |
HK1256116A1 (zh) | 抗lag-3抗體 | |
GB201521391D0 (en) | Antibodies | |
GB201521393D0 (en) | Antibodies | |
GB201503534D0 (en) | Novel method | |
HK1232136A1 (zh) | 融合蛋白 | |
HK1246804A1 (zh) | Tau結合抗體 | |
GB201521382D0 (en) | Antibodies | |
IL247322A0 (en) | Antibodies to complement factor bb | |
GB201512372D0 (en) | Novel method | |
HK1255056A1 (zh) | 抗cd115抗體 | |
HK1243429A1 (zh) | 抗前-s1 hbv抗體 | |
HK1250724A1 (zh) | 用於製備經修飾的血管性血友病因子的方法 | |
GB201508180D0 (en) | Antibodies | |
EP3164150A4 (en) | Modified von willebrand factor | |
GB201515745D0 (en) | Proteins | |
GB201511787D0 (en) | Proteins | |
IL258981A (en) | Methods for the production of proteins | |
GB201509907D0 (en) | Antibodies | |
GB201513033D0 (en) | Proteins | |
HK1244292A1 (zh) | 具有改善的半衰期的經修飾的血管性血友病因子 | |
GB201522394D0 (en) | Antibodies | |
GB201503438D0 (en) | Antibodies | |
AU2014902532A0 (en) | Modified von willebrand factor |